Forbin
Senior Member (Voting Rights)
This is a New York Times news story, not a scientific paper - so I'm not sure if this the right place to post this.
A Cancer Trial’s Unexpected Result: Remission in Every Patient
https://www.nytimes.com/2022/06/05/health/rectal-cancer-checkpoint-inhibitor.html
At Memorial Sloan Kettering Cancer Center, 18 of 18 patients with rectal cancer caused by "a deficiency in mismatch repair" had (apparently total) remissions following treatment with a drug called "dostarlimab."
It was a small trial with no control group, but the results have been called "unheard-of."
Link to the paper in The New England Journal of Medicine here: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
[ The paper refers to success in 12 of 12 patients, so I assume that six more patients had equivalent results following the paper's submission. ]
[ ETA: This is not a treatment for all types of rectal cancer. The type of cancer treated in this study only represents about 5% to 10% of all rectal cancers. ]
A Cancer Trial’s Unexpected Result: Remission in Every Patient
https://www.nytimes.com/2022/06/05/health/rectal-cancer-checkpoint-inhibitor.html
At Memorial Sloan Kettering Cancer Center, 18 of 18 patients with rectal cancer caused by "a deficiency in mismatch repair" had (apparently total) remissions following treatment with a drug called "dostarlimab."
It was a small trial with no control group, but the results have been called "unheard-of."
Link to the paper in The New England Journal of Medicine here: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
[ The paper refers to success in 12 of 12 patients, so I assume that six more patients had equivalent results following the paper's submission. ]
[ ETA: This is not a treatment for all types of rectal cancer. The type of cancer treated in this study only represents about 5% to 10% of all rectal cancers. ]
Last edited: